Yun-song Yang
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.
Journal: Science translational medicine
Published: September 10, 2025
Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets.
Journal: Cell discovery
Published: March 14, 2025
TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.
Journal: Oncogene
Published: March 04, 2025
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: September 13, 2023
Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 07, 2022
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
Journal: Cancer research
Published: July 03, 2022
The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
Journal: Breast cancer research and treatment
Published: November 03, 2021
HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.
Journal: Clinical and translational medicine
Published: October 28, 2021
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: May 30, 2021
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Journal: Cell research
Published: May 07, 2021
Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated-PI3Kα in early and advanced HER2-positive breast cancer.
Journal: Clinical and translational medicine
Published: April 18, 2021
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Journal: Oncogene
Published: July 14, 2020
Last Updated: 09/26/2026